Todd Asset Management LLC Lowers Stock Position in AbbVie Inc. $ABBV

Todd Asset Management LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 1.8% during the third quarter, HoldingsChannel.com reports. The fund owned 224,317 shares of the company’s stock after selling 4,169 shares during the period. Todd Asset Management LLC’s holdings in AbbVie were worth $51,938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at approximately $39,000. Finally, Access Investment Management LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at approximately $44,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of AbbVie stock opened at $231.57 on Monday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The business has a 50 day moving average price of $223.56 and a 200 day moving average price of $221.07. The company has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a P/E/G ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the business posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on ABBV. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, Morgan Stanley increased their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $251.00.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.